Decoy Therapeutics
DCOY
3 hedge funds and large institutions have $18.6M invested in Decoy Therapeutics in 2017 Q3 according to their latest regulatory filings, with 0 funds opening new positions, increasing their positions, reducing their positions, and 0 closing their positions.
0% more funds holding
Funds holding: 3 → 3 (0)
0% more ownership
Funds ownership: 0% → 0% (0%)
3% less capital invested
Capital invested by funds: $19.2M → $18.6M (-$601K)
100% less call options, than puts
Call options by funds: $0 | Put options by funds: $17K
Top Buyers
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
TCM
Tekla Capital Management
Boston,
Massachusetts
|
-$614K |
| 2 |
PP
Paloma Partners
Greenwich,
Connecticut
|
-$154K |
| 3 |
LP
LMR Partners
London,
United Kingdom
|
-$104K |
| 4 |
Goldman Sachs
New York
|
-$87K |
| 5 |
Susquehanna International Group
Bala Cynwyd,
Pennsylvania
|
-$49K |
DCOY Hedge Fund Activity: Q3 2017 in Review
3 of the 4,022 institutional investors tracked by Wall St. Rank reported a position in Decoy Therapeutics (DCOY) for Q3 2017, worth a combined $18.6M — down 3.1% from $19.2M a quarter earlier.
Fund positioning in DCOY was balanced in Q3 2017: 0 funds opened new positions, 0 closed out, 0 added to existing stakes and 0 trimmed.
The largest seller was Tekla Capital Management, cutting an estimated $614K.
- 3 institutional investors held Decoy Therapeutics (DCOY) as of Q3 2017, unchanged from Q2 2017.
- Funds reported $18.6M of Decoy Therapeutics stock for Q3 2017, down 3.1% quarter-over-quarter.
- 0 funds opened new Decoy Therapeutics positions in Q3 2017 and 0 closed out.
- The largest Decoy Therapeutics seller in Q3 2017 was Tekla Capital Management, an estimated $614K sold.
Based on aggregated 13F filings for Q3 2017.